Liraglutide

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: approved drug label available

Storage

Follow Saxenda pen label storage; unopened pens are refrigerated and in-use storage/discard timing is product-specific.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Personal or family history of Medullary Thyroid Carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Personal or family history of thyroid C-cell tumors.
• Active or history of acute pancreatitis.
• Severe gastroparesis or clinically significant delayed gastric emptying.
• Type 1 diabetes mellitus.
• Diabetic ketoacidosis.
• Severe renal impairment (eGFR < 30 mL/min/1.73m²) or end-stage renal disease: not recommended due to risk of dehydration-mediated acute kidney injury compounding existing impairment.
• Severe hepatic impairment: limited safety data; use not recommended.
• Pregnancy: animal studies show fetal harm; contraindicated; discontinue prior to planned conception.
• Breastfeeding: excreted in animal milk; avoid use.
• Known hypersensitivity or anaphylaxis to liraglutide or any formulation excipient.
• Concurrent use with any other GLP-1 receptor agonist (e.g., semaglutide, exenatide, dulaglutide): overlapping mechanism; additive GI toxicity.
• Concurrent use with any dual/triple incretin agonist: direct pharmacological conflict.
• Concomitant use of insulin or insulin secretagogues without dose reduction: significantly elevated hypoglycemia risk.
• Concomitant use of warfarin or oral medications with narrow therapeutic index: daily GI motility changes alter absorption kinetics.
• History of suicidal ideation or prior suicide attempts: monitor closely; behavioral changes reported in post-marketing data.
• Planned general anesthesia or elective surgery: delayed gastric emptying raises pulmonary aspiration risk; follow pre-operative fasting protocols.
• Pediatric use under age 12 (Victoza) or under age 12 for obesity (Saxenda): safety not established below approved age thresholds.
• Heart failure (NYHA Class IV): insufficient clinical data.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Nausea: most prevalent adverse effect; higher daily incidence than weekly agents due to constant receptor stimulation without peak/trough cycle; reported in up to 40% of subjects.
• Vomiting.
• Diarrhea.
• Constipation.
• Abdominal pain and cramping.
• Dyspepsia (indigestion).
• Abdominal distension and bloating.
• Decreased appetite and dysgeusia (altered taste).
• Belching and flatulence.
• Gastroparesis: delayed gastric emptying; clinically relevant for anesthesia planning.
• Gastroesophageal reflux disease (GERD) exacerbation.
• Injection site reactions: pain, erythema, bruising, and nodule formation; more pronounced than weekly agents due to daily injections cycling through limited rotation sites.
• Injection site fatigue: daily dosing exhausts viable injection site rotation faster than weekly protocols.
• Fatigue and lethargy: frequently secondary to caloric deficit.
• Headache.
• Dizziness.
• Hypoglycemia: rare in monotherapy; significant risk when combined with insulin or sulfonylureas.
• Acute pancreatitis: class risk; rare but documented; discontinue if severe upper abdominal pain develops.
• Acute kidney injury: primarily dehydration-mediated from GI fluid losses; monitor renal function in at-risk subjects.
• Cholelithiasis (gallstones) and acute cholecystitis: risk increases with dose and duration.
• Diabetic retinopathy complications: risk elevated in subjects with pre-existing retinopathy during rapid glycemic correction.
• Thyroid C-cell tumor risk: confirmed in rodent models; human risk not definitively established; monitor for neck mass, hoarseness, dysphagia, or dyspnea.
• Increased heart rate: modest mean increase of 2-3 BPM; less pronounced than glucagon-containing compounds.
• Alopecia (hair loss): reported in post-marketing surveillance.
• Anaphylaxis and angioedema: rare but documented.
• Pulmonary aspiration risk under general anesthesia: secondary to delayed gastric emptying.
• Reduced compliance over time: daily injection burden is the primary driver of protocol non-adherence compared to weekly alternatives.
• Rapid weight regain upon discontinuation: similar to other GLP-1 agents; expected without lifestyle maintenance.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
• https://www.nejm.org/doi/full/10.1056/NEJMoa1411892
• PubMed search: Liraglutide
• DailyMed label search: liraglutide